Intuitive Surgical is in a clear and sustained downtrend across every measured horizon. The stock is down 19.02% over the past year, 21.82% over six months, and 34.31% year-to-date, a severe underperformance against a SPY that gained 16.22% over one year and 12.08% YTD, producing a relative strength of -35.24% over 12 months and -46.39% YTD. At the current price of $369.15, the shares sit just 12.3% above the 52-week low of $328.57 and a striking 38.9% below the 52-week high of $603.88, placing the stock at roughly 14.4% of its 52-week range — a positioning that reflects persistent distribution and momentum-driven selling rather than a healthy pullback within an uptrend. The maximum drawdown of -44.0% confirms this is a deep correction, and while proximity to the low can attract value-oriented buyers, the absence of any base-building pattern means the stock remains a falling-knife risk until proven otherwise. Recent momentum is negative but shows tentative stabilization. The 1-month change of -8.00% and 3-month change of -10.20% are both negative, yet the 1-month decline is less severe than the 6-month (-21.82%) and YTD (-34.31%) figures, suggesting the pace of selling is decelerating rather than accelerating. The most recent sessions support this: the stock rallied 2.41% on the latest day to $369.15 from a prior close of $360.46, and it has recovered from the September 8 low of $350.16, a roughly 5.4% bounce off that trough. Relative strength remains deeply negative across all windows (-6.94% over 1 month, -13.24% over 3 months), so while the short-term bounce is constructive, it has not yet translated into outperformance versus the market, and the 1-month trend remains directionally consistent with — not divergent from — the longer-term downtrend. Key technical levels are well defined by the 52-week range. Immediate support sits at the 52-week low of $328.57, roughly 11.0% below the current price; a decisive breakdown below that level would signal capitulation and likely open the door to further downside, particularly given the stock's beta of 1.465, which implies roughly 46.5% more volatility than the S&P 500 and argues for smaller position sizes and wider stops. To the upside, initial resistance lies in the $400-$420 zone where the stock repeatedly stalled in June and August, with the 52-week high of $603.88 representing the full recovery target — some 63.6% above the current price. A breakout above $420 on above-average volume would be the first meaningful evidence of a trend reversal, while continued rejection at that level would reinforce the downtrend; the short ratio of 3.03 days-to-cover indicates only moderate short interest, so a squeeze is not a primary driver of upside risk.

Intuitive's revenue trajectory remains healthy even as the stock has de-rated. Q1 2026 revenue came in at $2.771 billion, up 22.96% year-over-year from $2.253 billion in Q1 2025, and the sequential progression through 2025 was consistently strong: $2.440 billion in Q2 2025, $2.505 billion in Q3 2025, and $2.866 billion in Q4 2025, with the Q1 2026 figure representing the second-highest quarterly revenue on record. The revenue mix is dominated by recurring, high-margin streams — instruments and accessories contributed $1.686 billion and services $434 million, versus just $651 million from systems — meaning roughly 76% of revenue is annuity-like and tied to procedure volumes rather than capital equipment cycles. This mix is the core of the bull case, but the market's July reaction to unchanged full-year guidance implies investors fear procedure growth is decelerating from the ~23% YoY pace, and consensus revenue estimates of $18.49 billion for the year imply only modest sequential acceleration from the current run-rate. Profitability remains elite. Q1 2026 net income was $821.5 million on a 29.65% net margin, with gross margin of 66.06% and operating margin of 30.87%, and EBITDA of $1.140 billion (41.16% of revenue). Margins have been remarkably stable — gross margin has hovered between 66.1% and 66.4% over the last four quarters, and net margin has ranged from 27.7% to 29.6% — with the Q1 2026 net margin actually expanding from 27.73% in Q4 2025 and 28.12% in Q3 2025. The one blemish is the Q1 2025 gross margin of 64.69%, which was depressed by one-time items, so the current 66% level represents normalization rather than deterioration; for a medical device company with a dominant platform, 66% gross and ~30% operating margins are best-in-class and reflect enormous pricing power on instruments and services. The balance sheet is fortress-like and cash generation is robust. Debt-to-equity is just 0.017, the current ratio is 4.87, and the company holds $2.052 billion in cash against negligible debt, giving it essentially no financial leverage risk. Free cash flow on a trailing-twelve-month basis is $2.834 billion, and quarterly free cash flow has been consistently strong ($808.6 million in Q1 2026, $730.0 million in Q4 2025, $735.6 million in Q3 2025), comfortably funding $103.3 million of quarterly capex and $1.123 billion of stock repurchases in Q1 2026 without external financing. ROE of 16.02% and ROA of 10.51% are solid though flattered by a low equity multiplier of ~1.15, and the company's ability to repurchase over $1 billion of stock in a single quarter while still growing cash demonstrates the self-funding nature of the business; the primary fundamental risk is not solvency but the sustainability of premium procedure growth against new competition.